TEAMM
Tackling Early Morbidity and Mortality in Myeloma:
Assessing the benefit of antibiotic prophylaxis and it's effect on healthcare asscoiated infection |
A randomised, multicentre, double blind, placebo-controlled trial |
| TEAMM is funded by the NIHR HTA and lead by professor Mark Drayson at the University of Birmimgham in conjunction with the University of Warwick Clinical Trials Unit |
